Labetuzumab govitecan

Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer[1][2][3].

Research Areas >> Cancer

Labetuzumab govitecan (总共 1.0 mg，腹腔注射) 可延长 GW-39 肺转移小鼠模型的中位生存期[2]。 Labetuzumab govitecan (25 mg/kg，腹腔注射，每周两次，持续 4 周) 可延长皮下 LS174T 异种移植裸鼠的中位生存期[2]。 Animal Model: sc LS174T Xenograft in nude mice Dosage: 25 mg/kg Administration: i.p. twice weekly for 4 weeks Result: Prolonged median survival. Animal Model: LS174T tumor xenograft model in nude mice (PK assay) Dosage: 0.25 mg Administration: i.v. Result: T1/2: 112.5 h; Cmax: 115 μg/mL; MRT: 147 h.

[1]. Dotan E, et al. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. J Clin Oncol. 2017 Oct 10;35(29):3338-3346.  

[2]. Govindan SV, et al. Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug. Mol Pharm. 2015 Jun 1;12(6):1836-47.  

[3]. Criscitiello C,et al. Antibody-drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021 Jan 28;14(1):20.